Agendia Announces Data Presented at ASCO 2020 Demonstrating Importance of Further Classification of Breast Cancers to Enable Precise Prognosis and Treatment

May 29, 2020

PRESS RELEASE Presentations outline how BluePrint​®​ genomic testing enables further categorization of HER2-positive cancer and reclassification of ER+ tumors for patients’ benefit FLEX registry reinforces the clinical and real-world utility of MammaPrint® and BluePrint to improve stratification of breast cancer patients   IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – MAY 29, 2020 – Agendia, Inc.,…

Read more

Long-term Follow Up Data from Groundbreaking MINDACT Study Continues to Demonstrate Clinical Utility of MammaPrint

PRESS RELEASE Median follow up nearing 9 years confirms MINDACT as a positive de-escalation study   IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – MAY 29, 2020 – Agendia, Inc., a world leader in precision oncology for breast cancer, today announced new data from MINDACT, the prospective, randomized trial designed to further demonstrate the clinical utility…

Read more

Agendia to Showcase New Data at ASCO 2020 That Further Stratifies Breast Cancer Patients for More Precise Therapy Recommendations

May 14, 2020

PRESS RELEASE Data adds to the growing body of evidence demonstrating the efficacy of Agendia’s MammaPrint® and BluePrint® testing to consistently inform optimal breast cancer treatment planning   IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – MAY 14, 2020 – Agendia, Inc., a world leader in precision oncology for breast cancer, announced today that they will…

Read more

Agendia Co-Founder and Chief Scientific Officer René Bernards, PhD Elected to the National Academy of Sciences

May 7, 2020

PRESS RELEASE Development of MammaPrint®, first FDA-cleared molecular diagnostic test for personalized treatment of breast cancer, considered a landmark achievement in breast cancer testing and treatment   Irvine, California and Amsterdam, Netherlands, May 07, 2020 – Agendia, Inc., a world leader in precision oncology for breast cancer, today announced that the Company’s Co-Founder and Chief…

Read more